Wolverine Blend.
A combination protocol pairing BPC-157's angiogenic and anti-inflammatory actions with TB-4's actin-regulatory and cell-migration signalling. The most widely used tissue repair stack in performance and recovery medicine — no human clinical trials for either compound yet.
Want the full narrative? Read the Wolverine Blend Research Guide for the published-study discussion and mechanism deep-dive.
- Compounds
- BPC-157 + TB-4
- Stack Type
- Tissue repair synergy
- Mechanisms
- Complementary, non-overlapping
- Class
- Peptide stack · research grade
- Status (UAE)
- Research-grade compounding
Two Signals, One Outcome.
BPC-157 drives angiogenesis via VEGF upregulation and suppresses COX-2; TB-4 sequesters G-actin, enabling cytoskeletal remodelling and directing cells to repair sites.
BPC-157 dominates the inflammatory phase; TB-4 the proliferative and remodelling phases — together covering the full repair cascade from day one through tissue rebuild.
The Wolverine stack entered sports medicine and recovery clinic protocols throughout the 2010s and is now among the most commonly combined peptide protocols worldwide.
Two Peptides, One Repair Blueprint.
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
C₆₂H₉₈N₁₆O₂₂ · MW 1419 Da
Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Glu-Thr-Glu-Val-Phe-Glu-Phe-Ser-Ser-Gly-Ser-Asn-Thr-Ser ···
C₂₁₂H₃₅₀N₅₆O₇₈S · MW 4964 Da
Strong solo. Untested together.
No human trials exist for either compound. Combination evidence is theoretical and anecdotal.
- Tendon & ligament repair confirmed
- Gut mucosal healing well-replicated
- Angiogenesis via VEGF pathway
- Anti-inflammatory (COX-2, PGE2)
- Systemic organ protection
- Wound closure accelerated
- Actin regulation confirmed
- Cardiac repair in MI models
- Corneal healing (human data)
- Cell migration to injury site
- Full repair cascade coverage
- No combination trial exists
- Clinical anecdote only
- Dosing ratio unstudied
Sign in to view the full research brief.
Mechanism deep-dive and research dosing protocols — available to registered researchers. It's free and takes under a minute.
Two orphans, one stack.
In the UAE, research-grade peptides occupy a defined regulatory category distinct from licensed medicines. Compounds sold under this classification — including those offered by Dubai Peptides — are intended exclusively for qualified research applications, not for human administration.
Neither BPC-157 nor TB-4 has been evaluated in a registered human clinical trial. All research has been conducted exclusively in rodent models, with no manufacturer-sponsored IND filings in the US, EU, or UAE. The "Wolverine Blend" is a community designation without formal scientific definition or regulatory classification of any kind.
BPC-157 and TB-4 studied independently across multiple labs; complementary tissue repair mechanisms established in rodent models.
Clinicians begin combining BPC-157 and TB-4 protocols; the "Wolverine" name enters peptide community use for the breadth of its profile.
A compounding market for this combination exists in the UAE, though no clinical trial for it has been registered in any jurisdiction.